Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureHanliang Zhang, Yizhou Huang, Zhenyuan Yang
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
10.1016/s0140-6736(21)02098-5 · 2021
Five-year survival outcomes with atezolizumab after chemotherapy in resected stage IB-IIIA non-small cell lung cancer (IMpower010): an open-label, randomized, phase III trial
10.1200/jco-24-01681 · 2025
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
10.1016/s1470-2045(22)00518-6 · 2022
Unresolved referenced work
Kept as external metadata until matched
Adjuvant durvalumab in completely resected early-stage non-small cell lung cancer
10.1200/jco-25-01828 · 2026
Adjuvant nivolumab vs observation in resected non-small cell lung cancer: a randomized clinical trial
10.1001/jama.2026.8992 · 2026
Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis
10.1200/jco.2014.55.2208 · 2014
How hazard ratios can mislead and why it matters in practice
10.1007/s10654-025-01250-9 · 2025
Hazards of hazard ratios—deviations from model assumptions in immunotherapy
10.1056/nejmc1716612 · 2018
Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer
10.1093/annonc/mdy075 · 2018
Interpretation of time-to-event outcomes in randomized trials: an online randomized experiment
10.1093/annonc/mdy462 · 2019
Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
10.1186/1471-2288-13-152 · 2013
Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data
10.1002/sim.6556 · 2015
Adjuvant immunotherapy improves survival in completely resected stage IB–III non-small-cell lung cancer: a systematic review and meta-analysis
2025
Immunotherapy for resectable non-small-cell lung cancer: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses
10.1016/j.esmoop.2025.105759 · 2025
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
2021
PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews
10.1186/s13643-020-01542-z · 2021
Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline
2020
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves
10.1186/1471-2288-12-9 · 2012
IPDfromKM: reconstruct individual patient data from published Kaplan–Meier survival curves
10.1186/s12874-021-01308-8 · 2021
Validating restricted mean survival time estimates from reconstructed Kaplan–Meier data against original trial individual patient data from trials conducted by the Canadian Cancer Trials Group
10.1016/j.jval.2021.12.004 · 2022
Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies
10.1186/s12874-015-0091-1 · 2015
CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials
10.1136/bmj-2022-073725 · 2023
PRISMA Harms Group. PRISMA harms checklist: improving harms reporting in systematic reviews
2016
10.1002/9781119536604.ch8
10.1002/9781119536604.ch8
ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis
10.1136/bmj-2023-076754 · 2023
The GRADE Working Group clarifies the construct of certainty of evidence
10.1016/j.jclinepi.2017.05.006 · 2017
GRADE certainty ratings: thresholds rather than categories of contextualization (GRADE Guidance 41)
10.7326/annals-25-00548 · 2025
No additional external references are available.